PathAI and Moffitt Cancer Center have formed a multi-year collaboration to advance cancer diagnostics through artificial intelligence and digital pathology.
Announced on Friday, PathAI will deploy its AISight Dx platform across Moffitt’s pathology programs, aiming to streamline workflows, enhance research, and strengthen cancer detection.
AISight Dx is a cloud-native digital pathology system that integrates enterprise-scale slide management, advanced viewing, and AI-powered collaboration.
It supports both laboratory operations and translational research, enabling faster, more accurate results. Additionally, the platform’s design allows for scalable implementation, helping institutions like Moffitt adopt AI-driven technologies without disrupting existing operations.
The partnership goes beyond technology adoption. It establishes a framework for joint research initiatives, real-world data collection, and clinical trial support. In addition, both organizations will explore biopharma collaborations and co-develop next-generation AI diagnostics that enhance precision medicine. This broad collaboration reflects Moffitt’s commitment to transforming oncology through cutting-edge science and innovation.
Andy Beck, MD, PhD, PathAI’s CEO and co-founder, emphasized the importance of the alliance. He said PathAI is equipping Moffitt’s pathologists with advanced tools that unlock insights from pathology data while supporting diagnoses and operational efficiency. Furthermore, he described the collaboration as an opportunity to drive innovation across multiple areas of cancer care.
Moffitt’s leadership echoed that enthusiasm. Karen Lu, MD, executive vice president and physician-in-chief, noted the move aligns with the center’s mission to prevent and cure cancer through transformative approaches. By adopting AISight Dx, Moffitt takes what she called a significant step toward integrating AI into oncology, ensuring faster and more accurate reviews by pathologists.
Read more: Breath Diagnostics pioneers novel lung cancer breath test
Read more: Breath Diagnostics takes aim at lung cancer with One Breath
Collaboration shows confluence of technology and expertise
William Westra, MD, vice chair of pathology at Moffitt, displayed the broader impact of digital transformation.
He said adopting advanced technologies will unlock extensive pathology data, which can then integrate seamlessly with imaging and clinical insights. Additionally, he underscored the partnership’s role in shaping future AI-powered care models and advancing oncology research.
Together, PathAI and Moffitt aim to redefine the role of digital pathology in cancer care. The collaboration shows how technology and clinical expertise can converge to improve patient outcomes and accelerate innovation. Furthermore, the initiative lays the groundwork for new approaches in precision medicine and next-generation cancer therapies.
PathAI remains a leader in AI and digital pathology, driving operational efficiency and enabling breakthroughs worldwide. Meanwhile, Moffitt continues its role as one of the nation’s top cancer centers, committed to advancing patient care through research and innovation. By combining their strengths, the two organizations seek to set a new standard for AI in oncology.
Over the past few years artificial intelligence has provided considerable assistance in the ongoing fight against cancer.
Companies using AI in oncology include startups like Immunai and Ketucky-based Breath Diagnostics, biopharmaceutical companies such as Achilles Therapeutics and Evaxion Biotech, and larger entities like GE HealthCare (NASDAQ: GEHC), Roche, NVIDIA (NASDAQ: NVDA), and Siemens Healthineers (ETR: SHL). These companies leverage AI for tasks such as developing new immunotherapies, improving drug discovery and development, enhancing diagnostic accuracy through radiomics and single-cell studies, and creating predictive models for early cancer detection and personalized treatment.
.
joseph@mugglehead.com
